Investigations
E

Optimization · Active

Driving down your cholesterol particles

Working on it together since February 2026

Active

Lipid management here targets apolipoprotein B, the count of atherogenic particles, rather than LDL cholesterol...

The current regimen pairs a PCSK9 inhibitor with bempedoic acid and ezetimibe, deliberately avoiding statins because of a separate...

Next step

Confirm the next ApoB draw and assess whether the non-statin regimen is holding particle count at the longevity target.

What we think is going on

One line of work is active.

01 / 01Reducing apolipoprotein (theWorking

Reducing apolipoprotein (the is active.

Reducing apolipoprotein B (the atherogenic-particle count) well below standard LDL-C targets lowers lifetime atherosclerotic cardiovascular risk.

What we're watching
No active actions on this line yet.
What you're doing

Nothing separate from the story cards right now.

Next step

Confirm the next ApoB draw and assess whether the non-statin regimen is holding particle count at the longevity target.